Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer
2009 (English)In: Oral Oncology, ISSN 1368-8375, E-ISSN 1879-0593, Vol. 45, no 1, 23-29 p.Article in journal (Refereed) Published
The aim of this study was to investigate the predisposition of the FGFR4 Gly/Arg polymorphism for development of head and neck squamous cell carcinoma (HNSCC) and, furthermore, to examine if the FGFR4 Arg(388) allele can be associated with resistance to chemo-and radiotherapy.
When analysing 110 tumour biopsies a significant 1.7-fold increased risk to develop HNSCC in individuals carrying the Gly(388) allele (p = 0.026) was found. Moreover a 2-fold increased risk for mates harbouring the Gly(388) allele (p = 0.031) to develop HNSCC was detected. In 39 HNSCC cell lines the role of the Arg(388) allele for radiation and cisplatin sensitivity was investigated. Our results show no rote of the Arg(388) allele for the radiosensitivity (p = 0.996) but indicate a tendency to increased cisplatin sensitivity (p = 0.141). When screening the transmembrane and kinase domains in the FGFR4 gene a novel mutation, probably generating a truncated protein lacking exons 14-18, was found in six of eight selected cell lines.
Taken together, we have here identified a marker that predicts the risk to develop HNSCC and possibly the sensitivity to cisplatin as well as a novel. mutation in the FGFR4 gene.
Place, publisher, year, edition, pages
Elsevier, 2009. Vol. 45, no 1, 23-29 p.
Oral tumours, Radiotherapy, Chemotherapy
Cancer and Oncology
IdentifiersURN: urn:nbn:se:liu:diva-16724DOI: 10.1016/j.oraloncology.2008.03.007ISI: 000262607900005PubMedID: 18487077OAI: oai:DiVA.org:liu-16724DiVA: diva2:160506